B7-33 Peptide: The Next Generation in Anti-Fibrotic and Cytoprotective Research

B7-33 is a cutting-edge research peptide, derived from the C-terminal region of human relaxin-2, that has rapidly captured the attention of the scientific community for its unique mechanisms and promising therapeutic potential. As a highly selective agonist of the relaxin family peptide receptor 1 (RXFP1), B7-33 is engineered to mimic the anti-fibrotic properties of native relaxin, but with greater stability and improved safety profile. Unlike traditional approaches, B7-33 provides potent tissue protection and anti-fibrotic activity while avoiding unwanted systemic effects, making it an exceptional candidate for preclinical and translational studies.

Emerging scientific studies have demonstrated that B7-33 exerts its powerful anti-fibrotic action by modulating key cellular pathways, including the inhibition of myofibroblast differentiation and suppression of excess collagen deposition. These actions are central to many chronic diseases characterized by pathological tissue scarring. Additionally, B7-33’s activation of RXFP1 has been shown to provide cytoprotective effects in cardiovascular, renal, and pulmonary systems, paving the way for a new era of peptide-based research.

Potential Benefits of B7-33:

• Selective activation of RXFP1, mimicking relaxin’s protective signaling with increased safety

• Powerful anti-fibrotic activity in multiple organ systems

• Inhibition of myofibroblast activation and reduction of excessive collagen synthesis

• Enhanced cytoprotective effects in response to tissue injury or oxidative stress

• Potential support of healthy cardiovascular, renal, and pulmonary function

• Improved peptide stability and bioavailability for reliable research outcomes

• Minimal risk of hypotensive or off-target hormonal effects

B7-33 Can Potentially Help With:

• Cardiac fibrosis (including post-myocardial infarction remodeling)

• Pulmonary fibrosis and lung scarring

• Renal fibrosis and chronic kidney disease

• Liver fibrosis, non-alcoholic steatohepatitis (NASH), and cirrhosis

• Acute or chronic heart failure

• Systemic sclerosis and related connective tissue disorders

• Inflammatory and fibrotic complications of metabolic syndrome

Advance your investigations with the uncompromising purity and quality of Peptide Nova’s B7-33. Order today and help shape the future of anti-fibrotic science.

*10MG Lyophilized Powder

THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.

*This product is intended for research use only. All Information on this website is for educational purposes only.

This product is not a food, drug, or supplement and may not be misbranded, misused or mislabeled as a food, drug, or supplement.